Yannick Fotio1,2, Roberto Ciccocioppo2, Daniele Piomelli3,4. 1. Department of Anatomy and Neurobiology, University of California, 837 Health Sciences Rd. Room 3101, 3216, Irvine, CA, 92697-4625, USA. 2. School of Pharmacy, Pharmacology Unit, University of Camerino, 62032, Camerino, Italy. 3. Department of Anatomy and Neurobiology, University of California, 837 Health Sciences Rd. Room 3101, 3216, Irvine, CA, 92697-4625, USA. piomelli@hs.uci.edu. 4. Department of Biological Chemistry, University of California, Irvine, CA, 92697-4625, USA. piomelli@hs.uci.edu.
Abstract
RATIONALE: N-acylethanolamine acid amidase (NAAA) is an intracellular cysteine hydrolase that terminates the biological actions of oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), two endogenous lipid-derived agonists of the nuclear receptor, and peroxisome proliferator-activated receptor-α. OEA and PEA are important regulators of energy balance, pain, and inflammation, but recent evidence suggests that they might also contribute to the control of reward-related behaviors. OBJECTIVES AND METHODS: In the present study, we investigated the effects of systemic and intracerebral NAAA inhibition in the two-bottle choice model of voluntary alcohol drinking and on operant alcohol self-administration. RESULTS: Intraperitoneal injections of the systemically active NAAA inhibitor ARN19702 (3 and 10 mg/kg) lowered voluntary alcohol intake in a dose-dependent manner, achieving ≈ 47% reduction at the 10 mg/kg dose (p < 0.001). Water, food, or saccharin consumption was not affected by the inhibitor. Similarly, ARN19702 dose-dependently attenuated alcohol self-administration under both fixed ratio 1 (FR-1) and progressive ratio schedules of reinforcement. Furthermore, microinjection of ARN19702 (1, 3 and 10 μg/μl) or of two chemically different NAAA inhibitors, ARN077 and ARN726 (both at 3 and 10 μg/μl), into the midbrain ventral tegmental area produced dose-dependent decreases in alcohol self-administration under FR-1 schedule. Microinjection of ARN19702 into the nucleus accumbens had no such effect. CONCLUSION: Collectively, the results point to NAAA as a possible molecular target for the treatment of alcohol use disorder.
RATIONALE: N-acylethanolamine acid amidase (NAAA) is an intracellular cysteine hydrolase that terminates the biological actions of oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), two endogenous lipid-derived agonists of the nuclear receptor, and peroxisome proliferator-activated receptor-α. OEA and PEA are important regulators of energy balance, pain, and inflammation, but recent evidence suggests that they might also contribute to the control of reward-related behaviors. OBJECTIVES AND METHODS: In the present study, we investigated the effects of systemic and intracerebral NAAA inhibition in the two-bottle choice model of voluntary alcohol drinking and on operant alcohol self-administration. RESULTS: Intraperitoneal injections of the systemically active NAAA inhibitor ARN19702 (3 and 10 mg/kg) lowered voluntary alcohol intake in a dose-dependent manner, achieving ≈ 47% reduction at the 10 mg/kg dose (p < 0.001). Water, food, or saccharin consumption was not affected by the inhibitor. Similarly, ARN19702 dose-dependently attenuated alcohol self-administration under both fixed ratio 1 (FR-1) and progressive ratio schedules of reinforcement. Furthermore, microinjection of ARN19702 (1, 3 and 10 μg/μl) or of two chemically different NAAA inhibitors, ARN077 and ARN726 (both at 3 and 10 μg/μl), into the midbrain ventral tegmental area produced dose-dependent decreases in alcohol self-administration under FR-1 schedule. Microinjection of ARN19702 into the nucleus accumbens had no such effect. CONCLUSION: Collectively, the results point to NAAA as a possible molecular target for the treatment of alcohol use disorder.
Authors: Ainhoa Bilbao; Antonia Serrano; Andrea Cippitelli; Francisco J Pavón; Andrea Giuffrida; Juan Suárez; Nuria García-Marchena; Elena Baixeras; Raquel Gómez de Heras; Laura Orio; Francisco Alén; Roberto Ciccocioppo; Benjamin F Cravatt; Loren H Parsons; Daniele Piomelli; Fernando Rodríguez de Fonseca Journal: Addict Biol Date: 2015-06-02 Impact factor: 4.280
Authors: María Antón; Alicia Rodríguez-González; Inmaculada Concepción Rodríguez-Rojo; Antoni Pastor; Ángeles Correas; Antonia Serrano; Antonio Ballesta; Francisco Alén; Raquel Gómez de Heras; Rafael de la Torre; Fernando Rodríguez de Fonseca; Laura Orio Journal: Addict Biol Date: 2017-11-27 Impact factor: 4.280
Authors: Laura M Best; Belinda Williams; Bernard Le Foll; Esmaeil Mansouri; Richard P Bazinet; Lin Lin; Vincenzo De Luca; Dina Lagzdins; Pablo Rusjan; Rachel F Tyndale; Alan A Wilson; Christian S Hendershot; Markus Heilig; Sylvain Houle; Junchao Tong; Stephen J Kish; Isabelle Boileau Journal: Neuropsychopharmacology Date: 2020-01-07 Impact factor: 7.853
Authors: F T Bonezzi; O Sasso; S Pontis; N Realini; E Romeo; S Ponzano; A Nuzzi; A Fiasella; F Bertozzi; D Piomelli Journal: J Pharmacol Exp Ther Date: 2016-01-14 Impact factor: 4.030